Sharon Flanagan

San Francisco

Featured in: Favicon

wiley.com

techcrunch.com Favicon

lexology.com Favicon

cslawreport.com Favicon

harvard.edu Favicon

pelawreport.com Favicon

onlinelibrary.wiley.com Favicon

corpgov.law.harvard.edu

Articles

Deal Outlook for 2024 Includes GLP-1 Investments, APAC M&A, and More Spinoffs

Feb 27, 2024 | lexology.com | Sharon Flanagan |Stephen Abreu |Robert Darwin |Carlton Fleming |Frank Rahmani |Meenakshi Datta | +3 more

Our lawyers share the top investment and regulatory trends from last month’s agenda-setting JP Morgan Health Care Conference. We expect an abundance of novel financing structures, investment focus on new disease states, and important new U.S. Food and Drug Administration (FDA) guidance. Regulatory developments in the U.S.: The FDA has issued several new policy documents on issues such as clinical trial design and conduct, affirming the agency’s high bar for approvals.
President Biden Signs Sweeping Artificial Intelligence Executive Order

Nov 7, 2023 | datamatters.sidley.com | Michael E. Borden |Colleen Brown |Sharon Flanagan |David Gordon

On October 30, 2023, President Joe Biden issued an executive order (EO or the Order) on Safe, Secure, and Trustworthy Artificial Intelligence (AI) to advance a coordinated, federal governmentwide approach toward the safe and responsible development of AI.
President Biden signs sweeping artificial intelligence Executive Order

Nov 6, 2023 | lexology.com | Michael E. Borden |Colleen Brown |Sharon Flanagan |David Gordon |Robert Keeling |David Lashway | +2 more

Table of ContentsOverviewKey DirectivesPrivacyEquity and Civil RightsIntellectual PropertySteps AheadOverviewOn October 30, 2023, President Joe Biden issued an executive order (EO or the Order) on Safe, Secure, and Trustworthy Artificial Intelligence (AI) to advance a coordinated, federal governmentwide approach toward the safe and responsible development of AI.
Key Components and Trends of CVRs in Life Sciences Public M&A Deals

Jun 16, 2023 | corpgov.law.harvard.edu | Sharon Flanagan |Sally Wagner Partin |Hannah Brown

Sally Wagner Partin and Sharon R. Flanagan are Partners and Hannah M. Brown is an Associate at Sidley Austin LLP. This post is based on their Sidley Austin memorandum. Related research from the Program on Corporate Governance includes Are M&A Contract Clauses Value Relevant to Target and Bidder Shareholders? (discussed on the Forum here) by John C. Coates, IV, Darius Palia, and Ge Wu; and The New Look of Deal Protection (discussed on the Forum here) by Fernan Restrepo, and Guhan Subramanian.